Hormone Replacement Therapy Over 60: Benefits & Risks

Dr. Shweta Patel, MD, FACOG

Board-certified OB/GYN • U.S. Navy veteran (13 years) • Author, The Book of Hormones • Founder, Gaya Wellness

Published August 5, 2025 • Updated May 3, 2026

If you are over 60 and deciding whether hormone replacement therapy belongs in your life, I want you to hear the real answer: it depends. That is the only medically honest answer.

I have seen women harmed by fear-based care. They were told they were “too old” for any hormone discussion, so their hot flashes, insomnia, painful sex, urinary symptoms, and bone loss were ignored. I have also seen women harmed by hype-based care. They were sold hormones as anti-aging medicine with no serious review of stroke risk, clot history, breast imaging, bleeding, dose, route, or uterus status.

Hormone replacement therapy over 60 is not one decision. Starting systemic estrogen for the first time at 67 is one decision. Continuing a low-dose patch that began at 52 is another. Treating vaginal and urinary symptoms with low-dose local estrogen is another. Using pellets with hard-to-adjust dosing is another. Those cannot be thrown into the same bucket.

Here is what I see in my practice: women do not need a panic script or a sales script. They need a physician who can look at the benefits, the risks, the formulation, and the woman sitting in front of her.

The Real Benefit of HRT Over 60

The most defensible reason to use systemic hormone therapy after menopause is symptom relief. Estrogen remains the most effective treatment for hot flashes and night sweats. When those symptoms continue into the 60s, they can disrupt sleep, concentration, mood, relationships, and daily function. That is not cosmetic medicine. That is quality-of-life medicine.

Some women also use hormone therapy for bone protection. Estrogen helps prevent bone loss and fracture, but I do not use that statement casually. If osteoporosis is the main issue, we still need to compare HRT with other bone medications, fall risk reduction, strength work, vitamin D status, protein intake, kidney function, and family history. Hormones may be part of the answer for selected women, but they are not the entire bone-health plan.

There is also the benefit women are often embarrassed to name: vaginal and urinary function. Dryness, burning, tearing, pain with intercourse, urgency, recurrent urinary symptoms, and loss of tissue resilience are common after menopause. These symptoms are not a relationship failure. They are estrogen-responsive tissue changes. For many women, local treatment changes daily life more than another supplement ever will.

At Gaya, I connect this conversation to hormone replacement therapy for women, menopause care, sexual health, and long-term function. The benefit I care about is not chasing youth. It is restoring the parts of a woman’s health that were dismissed as inevitable.

The Real Risk Is Not Just Age

Age matters, but age is not the whole risk profile. Clinicians become more cautious after 60 because baseline cardiovascular, clotting, stroke, and dementia risks rise with age. A small relative risk can become a larger absolute risk in an older population.

The Mayo Clinic explains the timing issue plainly: starting menopause hormone therapy at age 60 or older, or more than 10 years since menopause, increases the risk of serious complications. That does not mean every woman over 60 is automatically excluded. It means the threshold for a careful review is higher.

The risks I review include coronary heart disease, stroke, venous thromboembolism, breast cancer, gallbladder disease, abnormal uterine bleeding, endometrial cancer risk if estrogen is used without proper protection in a woman with a uterus, liver disease, and medication interactions. I also look at the story behind the prescription. Was it started for severe symptoms? Was it continued without reassessment? Was the dose escalated because labs were treated instead of symptoms?

Let me be clear: “natural,” “bioidentical,” and “custom” do not erase risk. The safety conversation depends on exposure, route, dose, medical history, and monitoring, not marketing language.

Starting After 60 Is Different From Continuing

This is the clinical distinction most women are never taught. If you started HRT near menopause and you are now 61, the question is not, “Are you past the age limit?” The better question is, “Do the benefits still outweigh the risks, and can we make the plan safer?”

NAMS states that hormone therapy does not need to be routinely discontinued in women older than 60 or 65. That matters. A hard stop can make some women miserable and can create rebound symptoms. But NAMS also emphasizes periodic reevaluation, individualized dosing, and risk review. Continuing is not the same as autopilot.

If you are starting systemic therapy for the first time after 60, I slow down. I want to know when menopause happened, whether symptoms are truly vasomotor, and whether sleep apnea, thyroid disease, depression, medication effect, alcohol, insulin resistance, or another driver is involved. I also want blood pressure, lipids, glucose markers, breast screening status, bleeding history, clot history, migraine aura, smoking, and family risk.

Inside Hormonal Agency™, this is exactly why the intake cannot be reduced to a single lab panel. Hormones are part of the case, not the entire case. For some women, the right move is systemic HRT. For others, the right move is vaginal estrogen only. For others, we treat sleep, blood pressure, weight, insulin resistance, or bone health first.

Route and Dose Change the Conversation

When a woman tells me she is “on hormones,” I need specifics. Oral estrogen, transdermal estradiol, vaginal estrogen, compounded cream, pellets, estrogen plus progesterone, estrogen alone after hysterectomy, and testosterone are different exposures.

Route matters. Oral estrogen passes through the liver first, which can affect clotting proteins, triglycerides, and inflammatory markers. Transdermal estradiol, such as a patch, gel, or spray, avoids that first-pass liver effect. In a woman over 60 who is an appropriate candidate for systemic estrogen, I often want to discuss whether transdermal therapy gives us a better risk strategy than oral therapy.

Dose matters too. More is not better medicine. The right dose is the lowest effective dose for the clinical goal, with enough follow-up to know whether it is working. I do not want women underdosed into suffering or pushed into supraphysiologic exposure because someone promised that high hormones equal vitality.

Uterus status matters. If you still have a uterus and use systemic estrogen, you usually need progesterone or another appropriate progestogen to protect the uterine lining. If you have had a hysterectomy, progesterone may not be necessary for endometrial protection. This is why I ask about hysterectomy, ovarian removal, bleeding, and prior procedures before I talk about prescriptions.

I am especially cautious with pellet therapy after 60 because dose adjustment is not immediate. If a patient develops bleeding, breast tenderness, mood changes, acne, hair changes, or concerning lab patterns, I want the ability to adjust quickly. In my view, reversibility is part of safety.

Vaginal Estrogen Is Its Own Category

Low-dose vaginal estrogen deserves a separate conversation from systemic HRT. It is used for genitourinary syndrome of menopause, not whole-body hot flashes. The goal is local tissue support: less dryness, less burning, less pain with sex, fewer tissue tears, improved comfort, and sometimes fewer urinary symptoms.

The American College of Obstetricians and Gynecologists describes both systemic and local options and recommends FDA-approved hormone therapy over compounded hormone therapy. That distinction matters because FDA-approved products have clearer dosing, labeling, and quality controls.

For a woman over 60 whose main complaint is painful sex or recurrent urinary discomfort, jumping to systemic estrogen may be the wrong level of treatment. A local option may address the tissue problem with much lower systemic absorption. Women with a history of estrogen-sensitive cancer still need specialist coordination, but “over 60” by itself should not shut down the conversation.

At Gaya, I connect this to vaginal rejuvenation, pelvic health, sexual medicine, and menopause care. The point is to stop dismissing treatable symptoms.

What the FDA Label Changes Do and Do Not Mean

In February 2026, the FDA approved labeling changes to six menopausal hormone therapy products. The agency removed boxed-warning risk statements related to cardiovascular disease, breast cancer, and probable dementia from those products after reviewing newer evidence.

That update matters because many women were counseled for years with language that did not separate younger symptomatic menopausal patients from older prevention-trial populations. The Women’s Health Initiative was important, but the average participant profile did not match every woman seeking treatment for bothersome symptoms near menopause.

But the FDA change is not a green light for casual prescribing. It does not mean risks disappeared or every woman over 60 should start hormones. It does not give compounded products the same evidence base as FDA-approved products. It means the conversation should become more accurate, individualized, and less fear-driven.

The old message was too blunt, and the new hype can be too blunt in the opposite direction. Women deserve better than both.

How I Build the Plan at Gaya

My first question is always, “What are we treating?” Hot flashes, insomnia, weight gain, low libido, vaginal pain, recurrent urinary symptoms, bone loss, brain fog, and mood changes can overlap, but they do not all require the same intervention.

Then I sort the clinical map: menopause timing, uterus status, ovarian status, prior HRT exposure, breast screening, bleeding history, clot history, stroke history, heart disease, blood pressure, lipids, A1c, liver function, migraine aura, tobacco, alcohol, family history, medications, and goals. If weight change and insulin resistance are part of the picture, I may bring in stubborn weight gain, metabolic health, or Weight Loss Concierge.

Some women need an HRT adjustment. Some need to switch from oral to transdermal. Some need progesterone corrected. Some need vaginal therapy rather than systemic escalation. Some need a nonhormonal hot-flash medication. Some need bone-specific therapy. Some need sleep apnea treated before anyone blames hormones.

That is why I built Hormonal Agency™ with physician management instead of a one-size-fits-all questionnaire. We look at hormones, symptoms, risk, labs, medication exposure, and long-term health together. For healthy aging, this may connect to Her Longevity, but I do not sell hormones as immortality. I use them when the indication, risk profile, and follow-up make sense.

What I Tell Women Over 60

If you are already on HRT and doing well, do not assume you must stop because of a birthday. Schedule a real review. Ask whether the dose is still appropriate, whether the route is still the safest fit, whether you still need progesterone, and whether your screening and risk factors are current.

If you want to start HRT for the first time after 60, expect a more careful evaluation. That caution is not dismissal. It is medicine. We may still treat, but we need to justify why systemic therapy is the right tool instead of local estrogen, nonhormonal treatment, bone medication, sleep treatment, metabolic care, or another approach.

If your clinician only says “never” or only says “everyone should,” find a better conversation. HRT over 60 has real benefits and real risks. The right plan respects both.

Dr. Shweta Patel, MD, FACOG

Board-certified OB/GYN, U.S. Navy veteran, and founder of Gaya Wellness. Dr. Patel leads physician-managed programs in hormone optimization, menopause hormone therapy, and longevity medicine for women in midlife and beyond.

You have not failed. Your plan did.